Bioceres Crop Solutions Statistics

Total Valuation

BIOX has a market cap or net worth of $284.71 million. The enterprise value is $539.16 million.

Market Cap	284.71M
Enterprise Value	539.16M

Important Dates

The last earnings date was Wednesday, May 21, 2025, before market open.

Earnings Date	May 21, 2025
Ex-Dividend Date	n/a

Share Statistics

BIOX has 62.71 million shares outstanding. The number of shares has decreased by -4.74% in one year.

Current Share Class	62.71M
Shares Outstanding	62.71M
Shares Change (YoY)	-4.74%
Shares Change (QoQ)	-0.59%
Owned by Insiders (%)	1.43%
Owned by Institutions (%)	16.20%
Float	35.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	47.79
PS Ratio	0.74
Forward PS	0.69
PB Ratio	0.92
P/TBV Ratio	13.50
P/FCF Ratio	7.28
P/OCF Ratio	6.14
PEG Ratio	3.98

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.13, with an EV/FCF ratio of 13.79.

EV / Earnings	n/a
EV / Sales	1.41
EV / EBITDA	13.13
EV / EBIT	24.05
EV / FCF	13.79

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.82
Debt / EBITDA	6.23
Debt / FCF	7.30
Interest Coverage	0.88

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	2.27%
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	$985,330
Profits Per Employee	-$23,281
Employee Count	389
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-9.49M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -57.25% in the last 52 weeks. The beta is 0.44, so BIOX's price volatility has been lower than the market average.

Beta (5Y)	0.44
52-Week Price Change	-57.25%
50-Day Moving Average	4.54
200-Day Moving Average	5.98
Relative Strength Index (RSI)	46.39
Average Volume (20 Days)	126,620

Short Selling Information

Short Interest	747,447
Short Previous Month	888,554
Short % of Shares Out	1.19%
Short % of Float	2.12%
Short Ratio (days to cover)	5.39

Income Statement

In the last 12 months, BIOX had revenue of $383.29 million and -$9.06 million in losses. Loss per share was -$0.14.

Revenue	383.29M
Gross Profit	150.30M
Operating Income	22.41M
Pretax Income	9.30M
Net Income	-9.06M
EBITDA	41.07M
EBIT	22.41M
Loss Per Share	-$0.14

Full Income Statement

Balance Sheet

The company has $31.20 million in cash and $285.64 million in debt, giving a net cash position of -$254.45 million or -$4.06 per share.

Cash & Cash Equivalents	31.20M
Total Debt	285.64M
Net Cash	-254.45M
Net Cash Per Share	-$4.06
Equity (Book Value)	346.33M
Book Value Per Share	4.94
Working Capital	n/a

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $46.36 million and capital expenditures -$7.25 million, giving a free cash flow of $39.11 million.

Operating Cash Flow	46.36M
Capital Expenditures	-7.25M
Free Cash Flow	39.11M
FCF Per Share	$0.62

Full Cash Flow Statement

Margins

Gross margin is 39.21%, with operating and profit margins of 5.85% and -2.36%.

Gross Margin	39.21%
Operating Margin	5.85%
Pretax Margin	-4.90%
Profit Margin	-2.36%
EBITDA Margin	10.72%
EBIT Margin	5.85%
FCF Margin	10.20%

Dividends & Yields

BIOX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	4.74%
Shareholder Yield	4.74%
Earnings Yield	-3.18%
FCF Yield	13.74%

Analyst Forecast

The average price target for BIOX is $8.63, which is 90.09% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$8.63
Price Target Difference	90.09%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	6.16%
EPS Growth Forecast (5Y)	64.43%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3